Goff, Laura W.
Azad, Nilofer S.
Stein, Stacey
Whisenant, Jennifer G.
Koyama, Tatsuki
Vaishampayan, Ulka
Hochster, Howard
Connolly, Roisin
Weise, Amy
LoRusso, Patricia M.
Salaria, Safia N.
El-Rifai, Wael
Berlin, Jordan D.
Funding for this research was provided by:
National Cancer Institute (UM1 CA186689, P30 CA068485)
Article History
Received: 22 June 2018
Accepted: 28 August 2018
First Online: 6 September 2018
Compliance with ethical standards
:
: LWG has served as a consultant for Celgene and has institutional research funding from Astellas Pharma, Pfizer, Onxy, SunPharma, Lilly, and Bristol-Myers Squibb. SS has participated in advisory boards for Genentech Roche and Merck. HH has served as a consultant for Bayer, Genentech, and Merck. RC has received research grants from Macrogenics, Novartis, Puma Biotechnology, Merck, Merrimack, and Genentech. JB has served as a consultant for Celgene, Genentech, Aduro, Boston Biomedical, Janssen, Cornerstone, Symphogen, and Bayer and has institutional research funding from Genentech, Abbvie, Taiho, Bayer, 5Prime, Phoenix, Incyte, and Vertex. For the remaining authors, none were declared.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained for all individual participants included in the study.